Prior to Fusion, Dr. Valliant founded the Centre for Probe Development and Commercialization (CPDC), a radiopharmaceutical research and development centre of excellence established in 2008 through funding from the Federal and Provincial governments, industry and academic partners. The CPDC is focused on discovering, developing and distributing the next generation of molecular imaging probes. The CPDC also plays an important role in Canada’s health care system, manufacturing and delivering a reliable, daily supply of imaging probes to hospitals and clinics nationally and internationally.
Dr. Valliant is also a Professor in the Department of Chemistry and Chemical Biology at McMaster University.
In 2009, Dr. Valliant was selected as one of Canada’s Top 40, Under 40, a distinction that recognizes his work at CPDC and McMaster University to advance molecular imaging probe technologies, improve patient care and spur economic growth through the commercialization of Canadian technologies. In 2015, he received the Brockhouse Canada Prize for Interdisciplinary Research in Science and Engineering from NSERC, recognizing his contribution to a team of researchers from physics, chemistry and nuclear medicine, who developed a breakthrough technology that uses hospital-based cyclotrons to produce critical medical isotopes.
Dr. Valliant completed his PhD at McMaster University, and followed with a post-doctoral fellowship under the joint supervision of professors Alun G. Jones (Harvard) and Alan Davison (MIT).
Dr. Burak’s experience has focused on integrating discovery and development processes to accelerate the identification and development of new therapeutic agents. He has submitted 14 Investigational New Drug Applications (INDs) and has developed two approved products across multiple therapeutic areas including oncology, cardiovascular, antibiotics, diseases of the central and peripheral nervous system, anesthesia/sedation, diabetes, and wound healing.
Dr. Burak holds a PhD in Analytical Chemistry from Temple University and a BSc in Chemistry from Drexel University.
Previously, she was a Senior Development Officer in the R&D group of Nordion (division acquired by BWXT), a global leader in medical isotopes and radiopharmaceuticals. At Nordion, Dr. Ferreira lead research in diagnostic and therapeutic radiopharmaceuticals both internally and through numerous external collaborations with industry and academia. Active in the nuclear medicine community, Dr. Ferreira has held numerous elected positions with the Society of Nuclear Medicine and Molecular Imaging including President of the Radiopharmaceuticals Science Council and member of the House of Delegates.
Dr. Ferreira holds a PhD in radiochemistry and an MBA in strategic management for the University of British Columbia.